The global succinylation of SARS-CoV-2-infected host cells reveals drug targets

SARS-CoV-2 感染宿主细胞的全局琥珀酰化揭示了药物靶点

阅读:7
作者:Quan Liu, Heming Wang, He Zhang, Liyan Sui, Letian Li, Wang Xu, Shouwen Du, Pengfei Hao, Yuhang Jiang, Jing Chen, Xiaoyun Qu, Mingyao Tian, Yinghua Zhao, Xuerui Guo, Xingye Wang, Wu Song, Guangqi Song, Zhengkai Wei, Zhijun Hou, Guoqing Wang, Minhua Sun, Xiao Li, Huijun Lu, Xinyu Zhuang, Ningyi Jin, 

Abstract

SARS-CoV-2, the causative agent of the COVID-19 pandemic, undergoes continuous evolution, highlighting an urgent need for development of novel antiviral therapies. Here we show a quantitative mass spectrometry-based succinylproteomics analysis of SARS-CoV-2 infection in Caco-2 cells, revealing dramatic reshape of succinylation on host and viral proteins. SARS-CoV-2 infection promotes succinylation of several key enzymes in the TCA, leading to inhibition of cellular metabolic pathways. We demonstrated that host protein succinylation is regulated by viral nonstructural protein (NSP14) through interaction with sirtuin 5 (SIRT5); overexpressed SIRT5 can effectively inhibit virus replication. We found succinylation inhibitors possess significant antiviral effects. We also found that SARS-CoV-2 nucleocapsid and membrane proteins underwent succinylation modification, which was conserved in SARS-CoV-2 and its variants. Collectively, our results uncover a regulatory mechanism of host protein posttranslational modification and cellular pathways mediated by SARS-CoV-2, which may become antiviral drug targets against COVID-19.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。